Page 177 - Read Online

Page 24 of 29 Dastidar et al. Vessel Plus 2020;4:14 I http://dx.doi.org/10.20517/2574-1209.2019.36

Fibrogenesis Tissue Repair 2010;3:12.
41. Wagner M, Wiig H. Tumour interstitial fluid formation, characterization, and clinical implications. Front Oncol 2015;5:115.
42. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors:
significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
43. Clauss MA, Jain RK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res 1990;50:3487-92.
44. Golombek SK, May JN, Theek B, Appold L, Drude N, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug
Deliv Rev 2018;130:17-38.
45. Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, et al. Thirty years of cancer nanomedicine: success, frustration, and hope.
Cancers (Basel) 2019;11:1855.
46. Zanotelli MR, Reinhart-King CA. Mechanical forces in tumor angiogenesis. Adv Exp Med Biol 2018;1092:91-112.
47. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, et al. Causes, consequences, and remedies for growth-induced
solid stress in murine and human tumors. Proc Natl Acad Sci U S A 2012;109:15101-8.
48. Zuo H. iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J Oncol 2019;2019:9367845.
49. Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumour targeting. Nanomedicine (Lond) 2013;8:1509-28.
50. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25:2677-81.
51. Chen Z, Zheng Y, Shi Y, Cui Z. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl)
gemcitabine-incorporated solid lipid nanoparticles. Int J Nanomedicine 2018;13:319-36.
52. Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 2016;8:776-91.
53. Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, et al. Dose recommendations for anticancer drugs in patients with
renal or hepatic impairment. Lancet Oncol 2019;20:e200-7.
54. De Angelis C. Side effects related to systemic cancer treatment: are we changing the Promethean experience with molecularly targeted
therapies? Curr Oncol 2008;15:198-9.
55. Golombek SK, May JN, Theek B, Appold L, Drude N, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug
Deliv Rev 2018;130:17-38.
56. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in
vitro and in vivo evaluation. J Control Release 2009;133:11-7.
57. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer
Res 2004;10:7677-84.
58. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230-4.
59. Hu H, Wang B, Lai C, Xu X, Zhen Z, et al. iRGD-paclitaxel conjugate nanoparticles for targeted paclitaxel delivery. Drug Dev Res
2019;80:1080-8.
60. Mangaiyarkarasi R, Chinnathambi S, Karthikeyan S, Aruna P, Ganesan S. Paclitaxel conjugated Fe 3 O 4 @LaF3:Ce ,Tb nanoparticles as
3+
3+
bifunctional targeting carriers for cancer theranostics application. J Magnetism Magnetic Materials 2016;399:207-15.
61. Dalela M, Shrivastav TG, Kharbanda S, Singh H. pH-sensitive biocompatible nanoparticles of paclitaxel-conjugated poly(styrene-co-
maleic acid) for anticancer drug delivery in solid tumors of syngeneic mice. ACS Appl Mater Interfaces 2015;7:26530-48.
62. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic
accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92.
63. Laitakari J, Näyhä V, Stenbäck F. Size, shape, structure, and direction of angiogenesis in laryngeal tumour development. J Clin Pathol
2004;57:394-401.
64. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26:489-502.
65. Ziyad S, Iruela-Arispe ML. Molecular mechanisms of tumor angiogenesis. Genes Cancer 2011;2:1085-96.
66. Azzopardi EA, Ferguson EL, Thomas DW. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J
Antimicrob Chemother 2013;68:257-74.
67. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
68. Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, et al. Upregulation of EGFR signaling is correlated with tumor stroma
remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res 2015;17:141.
69. Dastidar DG, Das A, Datta S, Ghosh S, Pal M, et al. Paclitaxel-encapsulated core-shell nanoparticle of cetyl alcohol for active targeted
delivery through oral route. Nanomedicine (Lond) 2019;14:2121-50.
70. Sun Q, Ojha T, Kiessling F, Lammers T, Shi Y. Enhancing tumor penetration of nanomedicines. Biomacromolecules 2017;18:1449-59.
71. Zhang YR, Lin R, Li HJ, He WL, Du JZ, et al. Strategies to improve tumor penetration of nanomedicines through nanoparticle design.
Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019;11:e1519.
72. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug
SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 2009;39:756-66.
73. Leffler CW, Parfenova H, Jaggar JH. Carbon monoxide as an endogenous vascular modulator. Am J Physiol Heart Circ Physiol
2011;301:H1-11.
74. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with
angiotensin II. J Natl Cancer Inst 1981;67:663-9.
75. Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, et al. NO to cancer: The complex and multifaceted role of nitric oxide and the
epigenetic nitric oxide donor, RRx-001. Redox Biol 2015;6:1-8.